Tarsier Pharma to Present P-III (TRS4VISION) Trial Results of TRS01 for Noninfectious Anterior Uveitis Including Patients with Uveitic Glaucoma at IOIS 2023
Shots:
- The P-III (TRS4VISION) trial evaluating the safety & efficacy of TRS01 eye drops in a ratio (2:1) in 142 patients with active noninfectious anterior uveitis incl. patients with uveitic glaucoma at 30 clinical sites across the US & EU for 4wks., followed by 2wk. follow up period
- TRS01 showed clear anti-inflammatory activity in noninfectious anterior uveitis with no evidence of significant adverse effects. The 2EPs measures key inflammation-related parameters were observed to be comparable to steroids although 1EPs of ACC=0 at 4wk. was not met
- The overall results deliver a risk-benefit product profile of sustained resolution of inflammation and stable IOP (Intra Ocular Pressure). The therapy showed a favorable safety & tolerability profile
Ref: PR Newswire | Image: Tarsier Pharma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
